---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020966"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:51:30.517688+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion

## Summary
- Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.
- First patient dosed in multi-dose portion of Phase I trial, evaluating safety of repeat administrations.
- Company intends to advance Decoy20 into combination studies with a checkpoint inhibitor.

## SEC filing metadata
- accession: 0001493152-24-020966
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/0001493152-24-020966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020966
- JSON: https://secwatch.observer/filing/0001493152-24-020966.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.